6:10 PM
 | 
Jan 07, 2013
 |  BC Extra  |  Clinical News

Peregrine gains on update of bavituximab trial 'discrepancies'

Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) jumped $1.08 (80%) to $2.43 on Monday after the company said an internal review determined that previously-announced issues in a Phase IIb trial of bavituximab plus docetaxel for second-line non-small cell lung cancer (NSCLC) did not affect the high-dose bavituximab arm. In September, shares of Peregrine plummeted 78%...

Read the full 241 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >